- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07721129
TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in Oman
Thrombolysis for Acute Ischemic Stroke Facilitated by TeleStroke: Oman TeleStroke Initiative
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Stroke is the second leading cause of death globally and the primary cause of long-term disability. Timely management of acute ischemic stroke (AIS) requires emergent administration of intravenous thrombolytics (alteplase or tenecteplase) within 4.5 hours of symptom onset, often followed by triage for possible thrombectomy. However, many peripheral hospitals, particularly in regions like Oman, lack the specialized neurological expertise necessary for this time-sensitive management.
Telemedicine, specifically 'TeleStroke,' has emerged as a crucial solution in numerous countries and communities to bridge this gap, enabling remote neurological support for acute stroke thrombolysis. The Oman TeleStroke Initiative aims to establish and evaluate the efficacy of such a network.
Study Objectives:
This study aims to:
Establish a TeleStroke 'hub' center within one or two major hospitals in Muscat with existing neurologic services.
Develop 'spoke' TeleStroke centers in five peripheral hospitals (Rustaq, Ibra, Buraimi, Ibri, and Sur) by identifying and engaging multidisciplinary participating teams (Internal Medicine, Emergency Medicine, Imaging, Laboratory, Nursing, Technical support).
Train senior physician-led teams at spoke hospitals in TeleStroke-based acute stroke management protocols, specifically focusing on intravenous thrombolysis.
Educate broader medical and paramedical teams in overall acute stroke management and decision-making processes.
Sequentially initiate acute stroke thrombolysis services at peripheral centers following a stepped-wedge trial model.
Conduct 3-5 mock TeleStroke-based stroke thrombolysis cycles at each peripheral center to ensure readiness and troubleshoot protocols.
Support and monitor 20 stroke care encounters for thrombolysis at each spoke center.
Document demographic data, stroke type and severity (NIH Stroke Scale, GCS), main neurologic deficits, risk factors, discharge outcome (neurologic deficits; NISS; modified Rankin Score), and 3-month outcome for two patient groups at each center: 30 patients receiving conventional management before TeleStroke initiation and 20 patients after TeleStroke-facilitated thrombolysis.
Conduct a comprehensive cost-benefit analysis.
Compare outcomes and cost-benefit between cohorts before and after TeleStroke initiation.
Facilitate handover of the project to a standing committee managed by participating hospitals upon project completion.
Study Design and Setting:
This is an implementation study utilizing a stepped-wedge randomized trial model. The project will establish a TeleStroke network comprising one or two expert 'hub' hospitals in Muscat linked to five 'spoke' hospitals in the periphery (Rustaq, Ibra, Buraimi, Ibri, and Sur). The sequential initiation of thrombolysis services at spoke centers under TeleStroke guidance will allow for observation of conventional management (control phase) followed by the intervention phase at each site.
Intervention and Training:
The intervention involves the implementation of a TeleStroke network and comprehensive training. At peripheral hospitals, 2-3 dedicated senior physicians from Internal Medicine and Emergency Medicine will be trained in acute stroke management, focusing on thrombolytic care. This training will include didactic lectures, case discussions, hands-on sessions (e.g., NIH Stroke Scale administration), CT evaluation in acute stroke, thrombolysis decision-making, post-thrombolysis care, and communication skills. Related medical and paramedical teams (Nursing, Physical Medicine) will also receive training in overall acute stroke and post-stroke patient management. Essential IT infrastructure (computers with audio-video, image/lab upload capabilities) will be provided, and a dedicated computer application for systematic communication and documentation will be adapted. Mock encounters will be practiced at each center to refine protocols and achieve short door-to-needle times.
Key Management Steps:
Eligible patients will undergo a rapid assessment including focused history ("last known to be normal" time), neurological exam (NIHSS, GCS), vital signs, and urgent investigations (blood glucose, CBC, U&E, ECG, CT brain plain, with CTA if available). If eligible for IV alteplase, consent will be obtained, and a TeleStroke consultation with a neurologist will be initiated. The remote neurologist will confirm eligibility, review imaging and labs, confirm consent, recommend the alteplase dose (0.9 mg/kg total, 10% bolus over 2 min, remainder over 1 hour), and guide post-dosing care. Patients will be monitored for BP, sensorium, deficits, and hemorrhage, with repeat CT at 24 hours or earlier if worsening. Patients with poor neurological status or complications may be transferred to a central hospital for expert care. Follow-up will extend to 3 months.
Endpoints of Interest:
Primary Outcomes:
Rate of utilization of IV alteplase thrombolysis for AIS at peripheral hospitals.
3-month clinical outcomes (Good=mRS 0-2; Poor=mRS 3-6) comparing control and rtPA groups.
Rates of intracranial or systemic hemorrhage.
Secondary Outcomes:
Discharge clinical outcomes (Good=mRS 0-2; Poor=mRS 3-6) comparing control and rtPA groups.
Time from patient arrival to initiation of TeleStroke Consult.
Door-to-Needle time for rtPA administration.
Rates of TeleStroke Consultations for acute stroke from peripheral hospitals.
Frequency of patient transfers to central hospitals.
Frequency of ICU admissions required.
Estimated cost of care: Comparison among Controls and rtPA Groups.
Statistical Analysis:
A stepped-wedge randomized model will guide implementation. Data from 30 patients managed conventionally will be documented at each center prior to thrombolysis initiation. After at least 20 thrombolysis encounters per peripheral hospital, overall outcomes will be analyzed. Continuous variables will be summarized using means/SDs or medians/quartiles, and categorical variables using frequencies/percentages. Analyses will be 2-tailed (p<0.05) using SPSS-21. Univariate methods will compare endpoints, and logistic regression will explore factors influencing outcomes. Cost-benefit analysis will compare TeleStroke-based management to conventional methods.
Significance to Oman and Benefits:
This initiative addresses a critical gap in acute ischemic stroke care by extending access to thrombolysis, currently largely inaccessible in many Omani peripheral communities. Successful implementation will align Omani stroke care with current international standards, potentially reducing stroke-related mortality and long-term morbidity. The expected reduction in long-term disability care costs is anticipated to offset program implementation and management expenses. This project will also foster ongoing skilled manpower development in acute care, telemedicine, and TeleStroke technology within Oman. While replicating studies conducted elsewhere, this research is vital to address local limitations such as telecommunications access, technological constraints, and community/hospital acceptability specific to Oman.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Arunodaya R Gujjar, MD, FRCP
- Número de telefone: +968 95154022
- E-mail: arunoday@squ.edu.om
Estude backup de contato
- Nome: Ali Al-Belushi, MD
- Número de telefone: +96896069012
- E-mail: altaweel1@hotmail.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age >18 years. Acute neurologic deficits due to cerebral ischemia/infarction. Clearly defined onset with duration from stroke onset of <4.5 hours. Significant neurological deficit (usually NIHSS score of 4-25).
Exclusion Criteria:
- CT brain shows showing evidence of intracranial hemorrhage
- CT brain showing acute or subacute infarct of size about >1/3 Middle Cerebral Artery territory.
- Arterial puncture at non compressible site in previous 7 days
- History of previous intracranial hemorrhage.
- Intracranial neoplasm, AV malformation, or aneurysm
- Recent head injury OR intracranial or intraspinal surgery in last 3 mo.
- Persistent Elevated BP >185/110 mm Hg despite treatment.
- Active ongoing internal bleeding.
- Platelet count <100 000/mm3.
- Current use of NOACs OR warfarin with INR >1.7 OR Inj.Enoxaparin/Heparin in therapeutic dose
- Blood glucose concentration <2.7mmol/L (<50mg/dl).
Relative contraindications: (may consider IV alteplase on individual evaluation).
- Seizure at onset with post ictal residual neurological deficit.
- Signs of mild stroke in isolation or rapidly improving symptoms.
- Pregnancy.
- Recent GI or UT hemorrhage within the last 21 days.
- Recent MI within previous 3 months (to exclude anterolateral infarct / STEMI)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Thrombolysis arm
This arm includes patients with Acute ischemic stroke treated with thrombolysis using TeleStroke consultation
|
Thrombolysis using TeleStroke consultation with Neurologist
Outros nomes:
|
|
Sem intervenção: Control Arm
This arm includes age, gender matched patients with Acute Ischemic stroke who are not treated by thrombolysis.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
90 day outcome
Prazo: 90 days
|
Clinical outcome on modified Rankin Score at 90 days.
This scale rates outcome from 0 to 6, with 0=no symptoms, 5=bed bound requiring assistance, 6=dead.
|
90 days
|
|
Discharge Outcome
Prazo: At discharge (assessed up to 5 days)
|
Clinical outcome on modified Rankin Score at discharge from hospital (assessed up to 5 days).
This scale rates outcome from 0 to 6, with 0=no symptoms, 5=bed bound requiring assistance, 6=dead.
|
At discharge (assessed up to 5 days)
|
|
Rate of Thrombolysis
Prazo: At admission and initial management- 2 hours
|
Rate of utilization of IV alteplase / tenecteplase thrombolysis for acute ischemic stroke at peripheral hospitals
|
At admission and initial management- 2 hours
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Intracranial Hemorrhage Rate
Prazo: 24 hours
|
Rate of symptomatic intracranial hemorrhage at 24 hours of IV thrombolysis
|
24 hours
|
|
Door to Needle time
Prazo: 1 hour
|
Time from Triage arrival of patient to time IV thrombolysis is initiated
|
1 hour
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Arunodaya R Gujjar, MD, DM, FRCP, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
- Diretor de estudo: Sanjay Jaju, MD, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
Publicações e links úteis
Publicações Gerais
- Demaerschalk BM, Berg J, Chong BW, Gross H, Nystrom K, Adeoye O, Schwamm L, Wechsler L, Whitchurch S. American Telemedicine Association: Telestroke Guidelines. Telemed J E Health. 2017 May;23(5):376-389. doi: 10.1089/tmj.2017.0006. Epub 2017 Apr 6.
- Ganguly SS, Gujjar AR, Al Harthi H, Al Hashmi A, Jaju S, Al-Mahrezi A, Al-Asmi AR. Risk Factors for Ischaemic Stroke in an Omani Community: A case-control study. Sultan Qaboos Univ Med J. 2021 Nov;21(4):585-590. doi: 10.18295/squmj.4.2021.043. Epub 2021 Nov 25.
- Gujjar AR, Lal D, Kumar S, Ganguly SS, Raniga S, Al-Azri F, Al-Asmi AR. Coexisting Dual Mechanisms of Ischaemic Stroke: Frequency and outcomes in a university hospital-based stroke registry. Sultan Qaboos Univ Med J. 2025 May 2;25(1):200-208. doi: 10.18295/2075-0528.2833.
- Commiskey P, Afshinnik A, Cothren E, Gropen T, Iwuchukwu I, Jennings B, McGrade HC, Mora-Guillot J, Sabharwal V, Vidal GA, Zweifler RM, Gaines K. Description of a novel telemedicine-enabled comprehensive system of care: drip and ship plus drip and keep within a system of stroke care delivery. J Telemed Telecare. 2017 Apr;23(3):428-436. doi: 10.1177/1357633X16637967. Epub 2016 Mar 16.
- Boulanger JM, Lindsay MP, Gubitz G, Smith EE, Stotts G, Foley N, Bhogal S, Boyle K, Braun L, Goddard T, Heran M, Kanya-Forster N, Lang E, Lavoie P, McClelland M, O'Kelly C, Pageau P, Pettersen J, Purvis H, Shamy M, Tampieri D, vanAdel B, Verbeek R, Blacquiere D, Casaubon L, Ferguson D, Hegedus Y, Jacquin GJ, Kelly M, Kamal N, Linkewich B, Lum C, Mann B, Milot G, Newcommon N, Poirier P, Simpkin W, Snieder E, Trivedi A, Whelan R, Eustace M, Smitko E, Butcher K. Canadian Stroke Best Practice Recommendations for Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care, 6th Edition, Update 2018. Int J Stroke. 2018 Dec;13(9):949-984. doi: 10.1177/1747493018786616. Epub 2018 Jul 18.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- AVC Isquêmico
- Derrame
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Fatores biológicos
- Hidrolases
- Enzimas
- Enzimas e coenzimas
- Proteínas sanguíneas
- Endopeptidases
- Hidrolases peptídicas
- Serina endopeptidases
- Serina proteases
- Ativadores de plasminogênio
- Fatores de coagulação do sangue
- Tenecteplase
- Ativador de Plasminogênio Tecidual
Outros números de identificação do estudo
- RC/SR-MED/MEDI/23/02
- SQU-EC/619/2021 MREC#2641 (Outro identificador: Sultan Qaboos University, Oman)
- MoH/CSR/21/25078 (Outro identificador: Ministry of Health, Oman)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .